Results 1 to 10 of about 8,187 (238)
Cefiderocol is a novel siderophore cephalosporin exhibiting potent antimicrobial activities. Although cefiderocol has not been approved in China, resistance is emerging.
Xueqing Wu, Xiaoting Hua, Lan Peng
exaly +3 more sources
In vivo efficacy of cefiderocol against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa carrying the AmpC E219K substitution [PDF]
Chromosomal AmpC variants selected during ceftolozane/tazobactam or ceftazidime/avibactam therapy may affect cefiderocol activity. We evaluated the impact of the E219K substitution on cefiderocol efficacy using isogenic Pseudomonas aeruginosa pairs in a ...
Arianna Rodríguez-Coello +14 more
doaj +2 more sources
Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations.
Yifan Wang, Deqing Yang
exaly +3 more sources
Cefiderocol/xeruborbactam is a novel β-lactam/β-lactamase inhibitor combination in which the siderophore-cephalosporin cefiderocol is paired with xeruborbactam, a broad-spectrum inhibitor that targets class A to D β-lactamases.
Lucía González-Pinto +10 more
doaj +2 more sources
Relative inhibitory activities of taniborbactam and xeruborbactam against KPC variants conferring reduced susceptibility or resistance to ceftazidime/avibactam, cefiderocol, and cefepime/taniborbactam [PDF]
The emergence of KPC variants associated with ceftazidime/avibactam resistance may also compromise the activity of other recently developed β-lactams, including cefiderocol and cefepime/taniborbactam. Xeruborbactam is a boronic acid β-lactamase inhibitor
Salud Rodríguez-Pallares +12 more
doaj +2 more sources
Paired In Vitro Susceptibility of Cefiderocol and Colistin in Colistin-Resistant, Extensively Drug-Resistant Gram-Negative Bacilli: A Single-Centre, MIC-Based Analysis of 236 Clinical Isolates [PDF]
Extensively drug-resistant (XDR) Gram-negative bacilli increasingly exhaust therapeutic options, leaving colistin and cefiderocol as last-resort agents.
Elena Hogea +6 more
doaj +2 more sources
Cefiderocol has been approved in the United States and Europe but not in China. We aim to evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to provide baseline data and investigate the resistance mechanism.
Longyang Jin, Hui Wang, Yuyao Yin
exaly +3 more sources
Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR ...
John H. Kimbrough +8 more
doaj +2 more sources
PiuA promoter mutations confer cefiderocol resistance in Acinetobacter baumannii: from in vitro evolution to global genomic screening [PDF]
IntroductionCarbapenem-resistant Acinetobacter baumannii (CRAB) poses a global health threat due to limited therapeutic options. Cefiderocol, a novel siderophore-conjugated cephalosporin, demonstrates potent in vitro activity against a variety of Gram ...
Xiaochen Liu +12 more
doaj +2 more sources
Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales that produce all kinds of carbapenemases and non-fermenting Gram-negative with difficult-to-treat resistance. As a β-lactam, its efficacy is optimized in extended-perfusion and requires dose adjustment in renal ...
Soriano, María Cruz +2 more
+5 more sources

